Mobile Technology for Community Health in Ghana: Is Maternal Messaging and Provider Use of Technology Cost-Effective in Improving Maternal and Child Health Outcomes at Scale?


Journal

Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882

Informations de publication

Date de publication:
13 02 2019
Historique:
received: 10 06 2018
accepted: 12 09 2018
revised: 12 09 2018
entrez: 14 2 2019
pubmed: 14 2 2019
medline: 18 12 2019
Statut: epublish

Résumé

Mobile technologies are emerging as tools to enhance health service delivery systems and empower clients to improve maternal, newborn, and child health. Limited evidence exists on the value for money of mobile health (mHealth) programs in low- and middle-income countries. This study aims to forecast the incremental cost-effectiveness of the Mobile Technology for Community Health (MOTECH) initiative at scale across 170 districts in Ghana. MOTECH's "Client Data Application" allows frontline health workers to digitize service delivery information and track the care of patients. MOTECH's other main component, the "Mobile Midwife," sends automated educational voice messages to mobile phones of pregnant and postpartum women. We measured program costs and consequences of scaling up MOTECH over a 10-year analytic time horizon. Economic costs were estimated from informant interviews and financial records. Health effects were modeled using the Lives Saved Tool with data from an independent evaluation of changes in key services coverage observed in Gomoa West District. Incremental cost-effectiveness ratios were presented overall and for each year of implementation. Uncertainty analyses assessed the robustness of results to changes in key parameters. MOTECH was scaled in clusters over a 3-year period to reach 78.7% (170/216) of Ghana's districts. Sustaining the program would cost US $17,618 on average annually per district. Over 10 years, MOTECH could potentially save an estimated 59,906 lives at a total cost of US $32 million. The incremental cost per disability-adjusted life year averted ranged from US $174 in the first year to US $6.54 in the tenth year of implementation and US $20.94 (95% CI US $20.34-$21.55) over 10 years. Uncertainty analyses suggested that the incremental cost-effectiveness ratio was most sensitive to changes in health effects, followed by personnel time. Probabilistic sensitivity analyses suggested that MOTECH had a 100% probability of being cost-effective above a willingness-to-pay threshold of US $50. This is the first study to estimate the value for money of the supply- and demand-side of an mHealth initiative. The adoption of MOTECH to improve MNCH service delivery and uptake represents good value for money in Ghana and should be considered for expansion. Integration with other mHealth solutions, including e-Tracker, may provide opportunities to continue or combine beneficial components of MOTECH to achieve a greater impact on health.

Sections du résumé

BACKGROUND
Mobile technologies are emerging as tools to enhance health service delivery systems and empower clients to improve maternal, newborn, and child health. Limited evidence exists on the value for money of mobile health (mHealth) programs in low- and middle-income countries.
OBJECTIVE
This study aims to forecast the incremental cost-effectiveness of the Mobile Technology for Community Health (MOTECH) initiative at scale across 170 districts in Ghana.
METHODS
MOTECH's "Client Data Application" allows frontline health workers to digitize service delivery information and track the care of patients. MOTECH's other main component, the "Mobile Midwife," sends automated educational voice messages to mobile phones of pregnant and postpartum women. We measured program costs and consequences of scaling up MOTECH over a 10-year analytic time horizon. Economic costs were estimated from informant interviews and financial records. Health effects were modeled using the Lives Saved Tool with data from an independent evaluation of changes in key services coverage observed in Gomoa West District. Incremental cost-effectiveness ratios were presented overall and for each year of implementation. Uncertainty analyses assessed the robustness of results to changes in key parameters.
RESULTS
MOTECH was scaled in clusters over a 3-year period to reach 78.7% (170/216) of Ghana's districts. Sustaining the program would cost US $17,618 on average annually per district. Over 10 years, MOTECH could potentially save an estimated 59,906 lives at a total cost of US $32 million. The incremental cost per disability-adjusted life year averted ranged from US $174 in the first year to US $6.54 in the tenth year of implementation and US $20.94 (95% CI US $20.34-$21.55) over 10 years. Uncertainty analyses suggested that the incremental cost-effectiveness ratio was most sensitive to changes in health effects, followed by personnel time. Probabilistic sensitivity analyses suggested that MOTECH had a 100% probability of being cost-effective above a willingness-to-pay threshold of US $50.
CONCLUSIONS
This is the first study to estimate the value for money of the supply- and demand-side of an mHealth initiative. The adoption of MOTECH to improve MNCH service delivery and uptake represents good value for money in Ghana and should be considered for expansion. Integration with other mHealth solutions, including e-Tracker, may provide opportunities to continue or combine beneficial components of MOTECH to achieve a greater impact on health.

Identifiants

pubmed: 30758296
pii: v21i2e11268
doi: 10.2196/11268
pmc: PMC6391645
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e11268

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

©Michelle Willcox, Anitha Moorthy, Diwakar Mohan, Karen Romano, David Hutchful, Garrett Mehl, Alain Labrique, Amnesty LeFevre. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 13.02.2019.

Références

Eur J Health Econ. 2013 Oct;14(5):789-97
pubmed: 22961230
JMIR Mhealth Uhealth. 2018 Jul 27;6(7):e153
pubmed: 30054263
Telemed J E Health. 2012 Jan-Feb;18(1):24-31
pubmed: 22150713
BMC Med Inform Decis Mak. 2017 Mar 14;17(1):27
pubmed: 28292288
Cir Cir. 2007 May-Jun;75(3):227-35
pubmed: 17659176
PLoS One. 2013 Jun 12;8(6):e65772
pubmed: 23776544
Health Policy Plan. 2005 Jan;20(1):25-34
pubmed: 15689427
PLoS Med. 2013;10(1):e1001362
pubmed: 23349621
Am J Prev Med. 2013 Nov;45(5):533-42
pubmed: 24139765
PLoS One. 2014 Jul 11;9(7):e102224
pubmed: 25014008
Health Policy Plan. 2001 Sep;16(3):326-31
pubmed: 11527874
PLoS One. 2012;7(12):e52045
pubmed: 23272206
Ophthalmology. 2013 Mar;120(3):566-573
pubmed: 23211635
Value Health. 2012 Jan-Feb;15(1 Suppl):S50-5
pubmed: 22265067
BMC Pregnancy Childbirth. 2014 Jul 22;14:243
pubmed: 25052536
Telemed J E Health. 2011 Dec;17(10):757-62
pubmed: 22011053
JAMA. 2014 Jul 16;312(3):229-30
pubmed: 24953141
PLoS One. 2012;7(4):e35560
pubmed: 22545117
Lancet. 2011 Sep 24;378(9797):1139-65
pubmed: 21937100
BMJ. 2002 Jun 15;324(7351):1434-7
pubmed: 12065269
J Med Internet Res. 2013 Jan 25;15(1):e17
pubmed: 23353680
J Acquir Immune Defic Syndr. 2014 Aug 15;66 Suppl 3:S306-10
pubmed: 25007201
Telemed J E Health. 2012 Oct;18(8):621-8
pubmed: 23061643
PLoS Med. 2013;10(1):e1001363
pubmed: 23458994
Bull World Health Organ. 2012 May 1;90(5):390-2
pubmed: 22589574
Asian Pac J Cancer Prev. 2014;15(13):5143-7
pubmed: 25040965
J Am Heart Assoc. 2015 Jan 05;4(1):e001213
pubmed: 25559011
Lancet. 2015 Jan 31;385(9966):430-40
pubmed: 25280870
Online J Public Health Inform. 2014 Feb 05;5(3):227
pubmed: 24678380
Bull World Health Organ. 2013 Oct 1;91(10):736-45
pubmed: 24115797
Lancet. 2016 May 14;387(10032):2049-59
pubmed: 26477328
J Zhejiang Univ Sci B. 2008 Jan;9(1):34-8
pubmed: 18196610
Arq Bras Cardiol. 2011 Oct;97(4):307-16
pubmed: 21808852
Int J Telemed Appl. 2016;2016:2515420
pubmed: 28070186
Lancet. 2005 Nov 26;366(9500):1882-4
pubmed: 16310555
Health Policy. 1996 Feb;35(2):123-43
pubmed: 10156650

Auteurs

Michelle Willcox (M)

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

Anitha Moorthy (A)

Grameen Foundation Ghana, Accra, Ghana.

Diwakar Mohan (D)

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

Karen Romano (K)

Grameen Foundation Ghana, Accra, Ghana.

David Hutchful (D)

Grameen Foundation Ghana, Accra, Ghana.

Garrett Mehl (G)

World Health Organization, Geneva, Switzerland.

Alain Labrique (A)

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

Amnesty LeFevre (A)

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Health Intelligence Initiative, Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH